SCHEMBL5470910

SCHEMBL5470910

Cc1ccc(S(=O)(=O)N(C)c2nccc(-c3cc(OCC(F)(F)F)ccc3OCC(F)(F)F)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
AKT1 P31749 2/20 0.41
PIK3CA P42336 2/20 0.41
MTOR P42345 2/20 0.41
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SCN9A Q15858 1/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
PTGS2 P35354 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467426 0.91 F2 (0.39) MEN1KMT2AALDH1A1HPGDAKT1
SCHEMBL5472490 0.81 ALDH1A1 (0.52) MEN1KMT2AALDH1A1HPGDAKT1
SCHEMBL5465185 0.77 ALDH1A1 (0.41) ALDH1A1HPGDPOLBSMN1; SMN2HTT
SCHEMBL5460284 0.74 ALDH1A1 (0.45) MEN1KMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL5472425 0.73 MAPT (0.44) ALDH1A1PTGS2NPSR1CYP1A2CYP2C9
SCHEMBL5471322 0.73 L3MBTL1 (0.46) MEN1KMT2AALDH1A1HPGDAKT1
SCHEMBL5476994 0.73 CYP17A1 (0.47) MEN1KMT2AALDH1A1HPGDPOLB
SCHEMBL5462677 0.72 AKT1 (0.39) MEN1KMT2AALDH1A1AKT1PIK3CA
SCHEMBL5470760 0.71 KDM4E (0.42) MEN1KMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL5467291 0.71 CCNT1 (0.44) MEN1KMT2AALDH1A1L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US claimed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP claimed
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR MEN1 2400/4885KMT2A 2631/4885ALDH1A1 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.